The Australian Research Data Commons (ARDC) invites you to participate in a short survey about your
interaction with the ARDC and use of our national research infrastructure and services. The survey will take
approximately 5 minutes and is anonymous. It’s open to anyone who uses our digital research infrastructure
services including Reasearch Link Australia.
We will use the information you provide to improve the national research infrastructure and services we
deliver and to report on user satisfaction to the Australian Government’s National Collaborative Research
Infrastructure Strategy (NCRIS) program.
Please take a few minutes to provide your input. The survey closes COB Friday 29 May 2026.
Complete the 5 min survey now by clicking on the link below.
Hematopoietic Cytokines For The Repair Of Myocardial Infarction
Funder
National Health and Medical Research Council
Funding Amount
$334,375.00
Summary
Heart attacks remain one of the most common causes of heart failure. Unlike many other tissues such as the skin or bone marrow, the heart is unable to repair itself following a heart attack. Recently it has been recognised that bone marrow cells can to a small degree repair the heart. How this is done is not known but it may be due to the formation of new blood vessels and perhaps new heart muscle. Unfortunately, the repair by bone marrow cells is not very efficient. One way of improving the eff ....Heart attacks remain one of the most common causes of heart failure. Unlike many other tissues such as the skin or bone marrow, the heart is unable to repair itself following a heart attack. Recently it has been recognised that bone marrow cells can to a small degree repair the heart. How this is done is not known but it may be due to the formation of new blood vessels and perhaps new heart muscle. Unfortunately, the repair by bone marrow cells is not very efficient. One way of improving the efficiency of heart repair by bone marrow cells is to give people bone marrow growth factors that increase the number of bone marrow cells in the blood and thus, increase the number at the site of heart injury. Our preliminary research shows that this is the case although the efficiency of repair is still not enough as a useful therapy. This project will examine how bone marrow growth factors improve heart repair following heart attacks and explore ways of improving the efficiency of repair to permit trials in humans.Read moreRead less
Integrated Basic And Clinical Cardiovascular Research For The Development Of Innovative Approaches To The Treatment Of Heart Failure
Funder
National Health and Medical Research Council
Funding Amount
$925,346.00
Summary
Heart failure (HF) is a common cardiovascular problem which causes disabling symptoms and reduces life expectancy. HF is the commonest cause or contributor to hospitalization in people over 65 years. For patients with advanced HF, survival is worse than that for aggresive cancers. At present, for patients with advanced HF and its complications, there are very few treatment options. Over the next 5 years I will conduct a comprehensive series of studies in animal models and in patients to develop ....Heart failure (HF) is a common cardiovascular problem which causes disabling symptoms and reduces life expectancy. HF is the commonest cause or contributor to hospitalization in people over 65 years. For patients with advanced HF, survival is worse than that for aggresive cancers. At present, for patients with advanced HF and its complications, there are very few treatment options. Over the next 5 years I will conduct a comprehensive series of studies in animal models and in patients to develop new treatment options.Read moreRead less
Proatherogenic CD4 NKT Cells And Atherosclerosis: Molecular Mechanisms And Therapeutic Strategies For Suppression
Funder
National Health and Medical Research Council
Funding Amount
$504,348.00
Summary
Immune cells called CD4+ iNKT cells are known to be activated by lipids which initiate development of atherosclerosis, a disorder of blood vessels which is responsible for most heart attacks and strokes. We aim to investigate how these cells contribute to the development of this important blood vessel disoder and examine potential ways of inhibiting their activation to prevent heart attacks and strokes.
Identification Of Novel Secretory Factors From The Heart As New Targets For Metabolic Disease
Funder
National Health and Medical Research Council
Funding Amount
$864,012.00
Summary
The incidence of obesity, type 2 diabetes and cardiovascular disease is rising at an alarming rate. The communication between the heart and distal tissues represents an exciting and emerging research area which has the potential to result in the identification of new targets and therapies. Here we will identify novel circulating proteins which could be developed as innovative therapies and ultimately translated into the clinic.
A Novel Therapy For The Prevention And Treatment Of Familial Hypertrophic Cardiomyopathy
Funder
National Health and Medical Research Council
Funding Amount
$835,972.00
Summary
Familial hypertrophic cardiomyopathy is a genetic disorder that leads to enlargement of the heart, cardiac failure and sudden death. No treatment exists that can reverse or prevent the cardiomyopathy. In this proposal we will determine whether a peptide (Patent WO2013/113060) targeting a calcium channel can prevent or reverse the cardiomyopathy as a novel treatment for the disease.
Mechanisms Underlying The Contribution Of Uremic Toxins To Cardiorenal Syndrome
Funder
National Health and Medical Research Council
Funding Amount
$413,533.00
Summary
Cardiorenal syndrome (CRS) is an umbrella term that defines disorders of the heart and kidneys whereby “acute or chronic dysfunction in one organ may induce acute or chronic dysfunction of the other”. We have demonstrated a significant association between heart and kidney fibrosis (scarring) and levels of a uremic toxin called indoxyl sulphate (IS), in relevant animal models and that blockade of production of this toxin reduces cardiac fibrosis. This project aims to explore this association.
Novel Therapy For Heart Failure With Preserved Ejection Fraction
Funder
National Health and Medical Research Council
Funding Amount
$1,068,984.00
Summary
Heart failure is a major cardiovascular problem. Up to half of the patients have a specific problem with heart muscle relaxation. There is no effective therapy for this type of heart failure. We will investigate the effects of new treatment approach using a range of experimental and clinical methods. If successful the treatment could move quickly into clinical practice.
Targeting A New Regulator Of Cardiac Pathology To Protect The Heart From Cardiac Dysfunction And Arrhythmia
Funder
National Health and Medical Research Council
Funding Amount
$717,857.00
Summary
Heart failure is associated with high mortality, and treatment of this condition represents a major unmet need. We recently reported that specific lipid species are elevated in hearts of mice with heart failure. The goal of this study is to comprehensively examine the therapeutic potential of targeting these lipid species with drugs.
Heart failure (HF) describes where the heart cannot pump adequately to meet the bodyÍs needs. Mortality remains high; therefore, there is an urgent need for new treatment approaches. The present grant aims to: (1) evaluate treatments for patients at high-risk for future development of HF (2) examine the ability to safely withdraw unnecessary HF drugs (3) focus on the effect of HF on the kidney via novel treatment strategies (4) examine the emerging role of cancer drugs in development of HF.